Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Poop pills could supercharge cancer immunotherapy

NCT ID NCT04758507

Disease control Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether transplanting gut bacteria from people who responded well to immunotherapy could help others with advanced kidney cancer respond better. Fifty participants received either a fecal transplant or a placebo. The goal was to see if the transplant could slow tumor growth and improve treatment outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fecal microbiota transplant (FMT) from donors responding to immunotherapy
What this could lead to
If it works, this could offer a way to boost the effectiveness of immunotherapy for advanced kidney cancer by changing the gut bacteria.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not apply to everyone. FMT carries risks of infection or side effects, and the benefit is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

50 people

The number who actually took part.

Started

Feb 2021

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed aRCC * Metastatic disease (measurable and not-measurable) * Radiological assessment within 8 wks before enrollment * Patient eligible to therapy with ICI for aRCC (or started within 8 wks) * Ability to provide written informed consent * Ability to be compliant with the scheduled procedures Exclusion Criteria: * Major comorbidities * Concomitant GI or autoimmune disorders, or HIV, HBV, HCV infection * Continuative corticosteroid therapy * Previous treatment with systemic immune-suppressants or immune-modulatory drugs * Antibiotic therapy within 4 weeks prior to enrollment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Renal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Renal cell carcinoma

Contacts and locations

Locations

  • Digestive Disease Center

    Rome, Rome, 00168, Italy

  • Gianluca Ianiro

    Rome, Rome, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.